Floatz logo

ANTI-CD32B MONOCLONAL ANTIBODY BI-1206

B-Cell Non-Hodgkin Lymphoma

Cancer Research UKmonoclonal_antibodyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

317 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

ANTI-CD32B MONOCLONAL ANTIBODY BI-1206 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
CCC
Indicative ·
50 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →